Dr. Cabanillas on Lenvatinib as First-Line Therapy for Patients With DTC

Maria E. Cabanillas, MD
Published: Saturday, Feb 20, 2016



Maria E. Cabinillas, MD, associate professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, discusses administering lenvatinib (Lenvima) as a first-line therapy for patients with differentiated thyroid cancer (DTC).

Lenvatinib is often used in both first- and second-line settings, Cabanillas explains. 

In clinical practice, Cabanillas often uses lenvatinib versus sorafenib in patients with aggressive disease that is rapidly progressing. However, both lenvatinib and sorafenib can be used as first-line treatments, she adds. 

<<< View more from the 2016 Multidisciplinary Head and Neck Cancer Symposium



Maria E. Cabinillas, MD, associate professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, discusses administering lenvatinib (Lenvima) as a first-line therapy for patients with differentiated thyroid cancer (DTC).

Lenvatinib is often used in both first- and second-line settings, Cabanillas explains. 

In clinical practice, Cabanillas often uses lenvatinib versus sorafenib in patients with aggressive disease that is rapidly progressing. However, both lenvatinib and sorafenib can be used as first-line treatments, she adds. 

<<< View more from the 2016 Multidisciplinary Head and Neck Cancer Symposium


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x